$DARE
Dare Bioscience, Inc.

2021 Q2 Form 10-Q Financial Statement

#000140191421000118 Filed on August 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $0.00 $731.0K
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.823M $1.580M
YoY Change 15.36% 7.48%
% of Gross Profit
Research & Development $7.340M $5.547M
YoY Change 32.32% 120.79%
% of Gross Profit
Depreciation & Amortization $3.020K $10.00K
YoY Change -69.8%
% of Gross Profit
Operating Expenses $9.163M $7.126M
YoY Change 28.59% 78.93%
Operating Profit -$9.163M -$7.126M
YoY Change 28.59% 78.93%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $175.00 $1.618K
YoY Change -89.18% -94.61%
Pretax Income -$9.163M -$7.120M
YoY Change 28.69% 80.25%
Income Tax
% Of Pretax Income
Net Earnings -$9.163M -$7.124M
YoY Change 28.61% 80.25%
Net Earnings / Revenue -974.58%
Basic Earnings Per Share -$0.18 -$0.27
Diluted Earnings Per Share -$0.18 -$0.27
COMMON SHARES
Basic Shares Outstanding 50.44M shares 26.71M shares
Diluted Shares Outstanding 50.44M shares 26.71M shares

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.112M $5.350M
YoY Change 70.31% -4.97%
Cash & Equivalents $9.112M $5.347M
Short-Term Investments
Other Short-Term Assets $1.992M $2.250M
YoY Change -11.46% 411.36%
Inventory
Prepaid Expenses $1.992M $2.253M
Receivables
Other Receivables $2.955M $177.1K
Total Short-Term Assets $14.06M $7.777M
YoY Change 80.78% 18.52%
LONG-TERM ASSETS
Property, Plant & Equipment $24.91K $54.85K
YoY Change -54.59% 674.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $738.3K $738.7K
YoY Change -0.05% 6.7%
Total Long-Term Assets $763.2K $793.5K
YoY Change -3.82% 13.46%
TOTAL ASSETS
Total Short-Term Assets $14.06M $7.777M
Total Long-Term Assets $763.2K $793.5K
Total Assets $14.82M $8.570M
YoY Change 72.95% 18.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $216.0K $1.714M
YoY Change -87.4% 172.08%
Accrued Expenses $4.370M $1.641M
YoY Change 166.34% 22.28%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $370.0K
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.005M $6.084M
YoY Change -1.3% 208.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.074M $2.180M
YoY Change -50.76% 968.9%
Total Long-Term Liabilities $1.074M $2.180M
YoY Change -50.76% 968.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.005M $6.084M
Total Long-Term Liabilities $1.074M $2.180M
Total Liabilities $7.078M $8.259M
YoY Change -14.3% 279.23%
SHAREHOLDERS EQUITY
Retained Earnings -$87.90M -$55.40M
YoY Change 58.66% 50.54%
Common Stock $145.8M $55.82M
YoY Change 161.11% 33.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.744M $311.3K
YoY Change
Total Liabilities & Shareholders Equity $14.82M $8.570M
YoY Change 72.95% 18.03%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$9.163M -$7.124M
YoY Change 28.61% 80.25%
Depreciation, Depletion And Amortization $3.020K $10.00K
YoY Change -69.8%
Cash From Operating Activities -$11.79M -$4.080M
YoY Change 188.93% 35.1%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$20.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$20.00K
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 13.26M 4.390M
YoY Change 201.97% -14.76%
NET CHANGE
Cash From Operating Activities -11.79M -4.080M
Cash From Investing Activities 0.000 -20.00K
Cash From Financing Activities 13.26M 4.390M
Net Change In Cash 1.468M 290.0K
YoY Change 406.2% -86.38%
FREE CASH FLOW
Cash From Operating Activities -$11.79M -$4.080M
Capital Expenditures $0.00 -$20.00K
Free Cash Flow -$11.79M -$4.060M
YoY Change 190.36% 34.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001401914
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q2 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q2 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
DARÉ BIOSCIENCE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity File Number
EntityFileNumber
001-36395
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4139823
dei Entity Address Address Line1
EntityAddressAddressLine1
3655 Nobel Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 260
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
926-7655
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92122
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
DARE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
70521979 shares
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9111741 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4669467 USD
CY2021Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2955425 USD
CY2020Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
460168 USD
CY2021Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1992054 USD
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1854277 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
14059220 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
6983912 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24907 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37930 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
738283 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
528870 USD
CY2021Q2 us-gaap Assets
Assets
14822410 USD
CY2020Q4 us-gaap Assets
Assets
7550712 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
216043 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1021333 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4369901 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3359718 USD
CY2021Q2 dare Deferred Grant Funding Current
DeferredGrantFundingCurrent
0 USD
CY2020Q4 dare Deferred Grant Funding Current
DeferredGrantFundingCurrent
1564553 USD
CY2021Q2 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
367285 USD
CY2021Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
1000000 USD
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
1000000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
418946 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
347712 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6004890 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7660601 USD
CY2021Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1000000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1000000 USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
73516 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
41844 USD
CY2021Q2 us-gaap Liabilities
Liabilities
7078406 USD
CY2020Q4 us-gaap Liabilities
Liabilities
8702445 USD
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57409523 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57409523 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41596253 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41596253 shares
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
5741 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
4159 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-107109 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-91388 USD
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
95762564 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
70366293 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-87917192 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-71430797 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
7744004 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-1151733 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14822410 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7550712 USD
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1797637 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1557548 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3737965 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3419313 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7340289 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5547450 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13068495 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7927254 USD
CY2021Q2 dare License Fee
LicenseFee
25000 USD
CY2020Q2 dare License Fee
LicenseFee
20833 USD
dare License Fee
LicenseFee
50000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-9162751 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7124213 USD
us-gaap Net Income Loss
NetIncomeLoss
-16486395 USD
us-gaap Net Income Loss
NetIncomeLoss
-11376461 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-8880 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
12090 USD
dare License Fee
LicenseFee
33333 USD
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
9162926 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
7125831 USD
us-gaap Operating Expenses
OperatingExpenses
16856460 USD
us-gaap Operating Expenses
OperatingExpenses
11379900 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9162926 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7125831 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-16856460 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-11379900 USD
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
175 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1618 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
178 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3439 USD
CY2021Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2020Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
369887 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15721 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-10854 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9171631 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7112123 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16502116 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11387315 USD
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50436593 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50436593 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26710750 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26710750 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47485980 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47485980 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25255073 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25255073 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-1151733 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
365911 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11324140 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
50400 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7323644 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-6841 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
3258233 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
405478 USD
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13251924 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-9162751 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-8880 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
7744004 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
440826 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
160841 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4252248 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-22944 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
3214183 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5222687 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1665020 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
186859 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4022336 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7124213 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
12090 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
311255 USD
us-gaap Net Income Loss
NetIncomeLoss
-16486395 USD
us-gaap Net Income Loss
NetIncomeLoss
-11376461 USD
us-gaap Depreciation
Depreciation
13023 USD
us-gaap Depreciation
Depreciation
23929 USD
us-gaap Share Based Compensation
ShareBasedCompensation
771389 USD
us-gaap Share Based Compensation
ShareBasedCompensation
347700 USD
dare Non Cash Lease Expense
NonCashLeaseExpense
-45270 USD
dare Non Cash Lease Expense
NonCashLeaseExpense
-90080 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
369887 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
2495256 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-378077 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
137777 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1144246 USD
dare Increase Decrease In Other Non Current Assets And Deferred Charges
IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges
61237 USD
dare Increase Decrease In Other Non Current Assets And Deferred Charges
IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges
-78513 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-805291 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
630899 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1012785 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-457901 USD
dare Increase Decrease In Deferred Grant Funding
IncreaseDecreaseInDeferredGrantFunding
1564553 USD
dare Increase Decrease In Deferred Grant Funding
IncreaseDecreaseInDeferredGrantFunding
74894 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20168469 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10684464 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15246 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15246 USD
dare Net Proceeds From Issuance Of Common Stock And Warrants
NetProceedsFromIssuanceOfCommonStockAndWarrants
24576064 USD
dare Net Proceeds From Issuance Of Common Stock And Warrants
NetProceedsFromIssuanceOfCommonStockAndWarrants
9245023 USD
dare Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
50400 USD
dare Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
1665020 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
367285 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24626464 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11277329 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-15721 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-10854 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4442274 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
566765 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4669467 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4780107 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9111741 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5346872 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
308533 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-87900000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9100000 USD
CY2021Q2 dare Working Capital Increase Deficit
WorkingCapitalIncreaseDeficit
8100000 USD
us-gaap Net Income Loss
NetIncomeLoss
-16500000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
20200000 USD
dare Periodof Insufficient Cashand Liquidity Requirements
PeriodofInsufficientCashandLiquidityRequirements
P12M
us-gaap Operating Lease Cost
OperatingLeaseCost
152000 USD
CY2021Q2 us-gaap Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
4391749 USD
dare Weighted Average Amortization Period
WeightedAverageAmortizationPeriod
P3Y21D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0087
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0064
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.24
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.22
CY2021Q2 dare Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0.000
dare Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0.000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.26
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.06
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
50000000.0 USD
CY2021Q2 dare Percentage Of Aggregate Commission
PercentageOfAggregateCommission
0.03
CY2018Q1 dare Percentage Of Aggregate Commission
PercentageOfAggregateCommission
0.030
CY2020Q2 dare Saleof Stock Maximum Amount Registered
SaleofStockMaximumAmountRegistered
7500000 shares
CY2021Q1 dare Saleof Stock Maximum Amount Registered
SaleofStockMaximumAmountRegistered
6400000 shares
CY2021Q2 dare Deferred Offering Costs Unamortized Portion
DeferredOfferingCostsUnamortizedPortion
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7000000.0 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
207000 USD
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.00
CY2019Q2 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
0.98
CY2020Q3 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
0.96
CY2019Q2 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
800000 USD
CY2020Q3 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
6863 USD
CY2021Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
52500 shares
dare Number Of Common Stock Warrants Exercised
NumberOfCommonStockWarrantsExercised
50000 shares
dare Number Of Common Stock Warrants Exercised
NumberOfCommonStockWarrantsExercised
1699000 shares
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1700000 USD
CY2021Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1856143 shares
CY2018Q3 us-gaap Net Rentable Area
NetRentableArea
3169 sqft
CY2021Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2018Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.07
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
419000 USD
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
151000 USD
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
76000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
286000 USD
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
114000 USD
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
110000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
226000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
238000 USD
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y21D
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
236000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
277000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
513000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
21000 USD
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
492000 USD
CY2020Q2 dare Coronavirus Aid Reliefand Economic Security Act Loan Proceeds Received
CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived
367285 USD
CY2021Q2 dare Notes Payable Current Plus Accrued Interest
NotesPayableCurrentPlusAccruedInterest
369887 USD
CY2018 dare Proceeds From Award Of Grant
ProceedsFromAwardOfGrant
1900000 USD
CY2020Q2 dare Proceeds From Award Of Grant
ProceedsFromAwardOfGrant
731000 USD
CY2021Q2 dare Deferred Grant Funding Current
DeferredGrantFundingCurrent
0 USD
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6512809 shares
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4801269 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6512809 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4801269 shares

Files In Submission

Name View Source Status
0001401914-21-000118-index-headers.html Edgar Link pending
0001401914-21-000118-index.html Edgar Link pending
0001401914-21-000118.txt Edgar Link pending
0001401914-21-000118-xbrl.zip Edgar Link pending
dare-20210630.htm Edgar Link pending
dare-20210630.xsd Edgar Link pending
dare-20210630_cal.xml Edgar Link unprocessable
dare-20210630_def.xml Edgar Link unprocessable
dare-20210630_g1.jpg Edgar Link pending
dare-20210630_htm.xml Edgar Link completed
dare-20210630_lab.xml Edgar Link unprocessable
dare-20210630_pre.xml Edgar Link unprocessable
exhibit311_20210630.htm Edgar Link pending
exhibit312_20210630.htm Edgar Link pending
exhibit321_20210630.htm Edgar Link pending
exhibit322_20210630.htm Edgar Link pending
ex_10106302021.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending